Autolus Therapeutics (NASDAQ:AUTL) Shares Down 5.2%

Shares of Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) traded down 5.2% during trading on Friday . The company traded as low as $4.53 and last traded at $4.55. 922,414 shares were traded during mid-day trading, a decline of 39% from the average session volume of 1,501,885 shares. The stock had previously closed at $4.80.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. Truist Financial lifted their target price on Autolus Therapeutics from $10.00 to $11.00 and gave the company a "buy" rating in a research note on Tuesday, April 9th. Needham & Company LLC reiterated a "buy" rating and set a $9.00 price objective on shares of Autolus Therapeutics in a research report on Friday, April 12th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Autolus Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $8.16.

Autolus Therapeutics Stock Down 5.8 %

The company has a 50-day moving average price of $5.89 and a 200-day moving average price of $5.09. The firm has a market capitalization of $1.20 billion, a price-to-earnings ratio of -3.80 and a beta of 1.90.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last released its earnings results on Thursday, March 14th. The company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.18). As a group, analysts forecast that Autolus Therapeutics plc will post -0.71 earnings per share for the current year.

Institutional Investors Weigh In On Autolus Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. UBS Group AG increased its holdings in shares of Autolus Therapeutics by 2.8% in the fourth quarter. UBS Group AG now owns 84,655 shares of the company's stock valued at $545,000 after buying an additional 2,345 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in shares of Autolus Therapeutics by 337.3% in the fourth quarter. BNP Paribas Financial Markets now owns 4,268 shares of the company's stock valued at $27,000 after buying an additional 3,292 shares in the last quarter. Cetera Investment Advisers increased its holdings in shares of Autolus Therapeutics by 2.9% in the first quarter. Cetera Investment Advisers now owns 141,600 shares of the company's stock valued at $261,000 after buying an additional 4,000 shares in the last quarter. EWA LLC increased its holdings in shares of Autolus Therapeutics by 40.2% in the fourth quarter. EWA LLC now owns 25,678 shares of the company's stock valued at $155,000 after buying an additional 7,361 shares in the last quarter. Finally, LPL Financial LLC increased its holdings in shares of Autolus Therapeutics by 39.2% in the fourth quarter. LPL Financial LLC now owns 32,300 shares of the company's stock valued at $61,000 after buying an additional 9,100 shares in the last quarter. 72.83% of the stock is currently owned by institutional investors and hedge funds.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.